NCT07181369 - A Phase 1 Study of GTX-B001 in Healthy Subjets and Patients With Cold Urticaria | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 31, 2025

Primary Completion Date

August 31, 2027

Study Completion Date

August 31, 2027

Conditions

Healthy SubjectsCold Urticaria

Interventions

DRUG

GTX-B001

Single infusion of one of up to five dosages of GTX-B001

DRUG

Normal Saline

Single infusion of normal saline

Trial Locations (2)

Charité Research Organization gmbh, Berlin

Fraunhofer Institute For Translational Medicine And Pharmacology, Berlin